Astria Therapeutics 2024 Corporate Presentation

Astria Therapeutics is developing first-choice therapeutics for patients with allergic and immunological diseases. The company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein for preventative treatment of hereditary angioedema (HAE), with early proof of concept showing a long-acting profile and dosing once every 3-6 months. The presentation outlines the Phase 1b/2 ALPHA-STAR trial progress and expected cash runway into mid-2027.